Corbus Pharmaceuticals Holdings, Inc. (CRBP) News
Follow Corbus Pharmaceuticals Holdings, Inc. (CRBP) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
Incidence and prevalence of OPSCC continue to rise in the U.S. largely driven by HPV infectionOPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L+ setting in the U.S. with approximately 14,000
NEWS | Sep 29, 2026, 12:09 PM UTC
M
Corbus Pharmaceuticals doses first patient in TEMPO-1 for CRB-701
Corbus Pharmaceuticals announced the first patient was dosed in its TEMPO-1 registrational study of CRB-701 in patients with 2L+ oropharyngeal cancer.
EQUITY | Sep 29, 2026, 12:03 PM UTC
L
Corbus Pharmaceuticals Stock Surges Ahead of Drug Data Readout
By Kelly CloonanShares of Corbus Pharmaceuticals rallied after the company said it would host a webcast to discuss topline data for a study for an obesity treatment.The stock was up 20% to $9.75 in late trading on Friday
EQUITY | Sep 11, 2026, 09:28 PM UTC
L
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDTNORWOOD, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP, a clinical-stage company focused on developing ne
NEWS | Sep 11, 2026, 08:02 PM UTC
L
CRBP - Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
CRBP - Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
NEWS | Sep 11, 2026, 08:01 PM UTC
L
Corbus (CRBP) reports inducement grants under Nasdaq Rule 5635(c)(4)
Corbus (CRBP) reports inducement grants under Nasdaq Listing Rule 5635(c)(4), per the company disclosure, with no additional terms or amounts provided in the feed.
REGULATION | Aug 17, 2026, 02:00 PM UTC
L
CRBP - Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
CRBP - Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
EARNINGS | Aug 06, 2026, 12:00 PM UTC
M
Corbus Pharmaceuticals Completes CANYON-1 Study
Corbus completes obesity treatment study
EQUITY | Aug 04, 2026, 12:31 PM UTC
L
Corbus Pharmaceuticals announces FDA clearance to initiate TEMPO-1 trial
Corbus Pharmaceuticals...
EQUITY | Jul 28, 2026, 01:12 PM UTC
L
CRBP Corbus Pharmaceuticals announces FDA clearance to initiate tempo-1 registrational study of crb-701 in patients with 2l oropharyngeal ca
CRBP Corbus Pharmaceuticals announces FDA clearance to initiate tempo-1 registrational study of crb-701 in patients with 2l oropharyngeal cancer Corbus Pharmaceuticals announces FDA clearance to initiate tempo-1 registra
REGULATION | Jul 28, 2026, 12:00 PM UTC
L
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (
EQUITY | Jul 06, 2026, 12:01 PM UTC